Avanos Medical (NYSE:AVNS) Updates Q4 Earnings Guidance

Avanos Medical (NYSE:AVNS) issued an update on its fourth quarter earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $0.38-0.43 for the period, compared to the consensus estimate of $0.40. The company issued revenue guidance of $175-180 million, compared to the consensus revenue estimate of $177.25 million. Avanos Medical also updated its Q4 2024 guidance to 0.380-0.430 EPS.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 3rd.

Avanos Medical Price Performance

Shares of NYSE:AVNS opened at $15.80 on Wednesday. The company has a market cap of $726.12 million, a price-to-earnings ratio of 46.47 and a beta of 0.99. Avanos Medical has a one year low of $14.98 and a one year high of $25.36. The firm has a fifty day moving average price of $17.70 and a two-hundred day moving average price of $20.87. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.